135 related articles for article (PubMed ID: 32928385)
1. UPLC-MS assessment on the structural similarity of recombinant human erythropoietin (rhEPO) analogues from manufacturers in China for attribute monitoring.
Alley W; Tao L; Shion H; Yu YQ; Rao C; Chen W
Talanta; 2020 Dec; 220():121335. PubMed ID: 32928385
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive glycan analysis of twelve recombinant human erythropoietin preparations from manufacturers in China and Japan.
Cowper B; Li X; Yu L; Zhou Y; Fan WH; Rao CM
J Pharm Biomed Anal; 2018 May; 153():214-220. PubMed ID: 29502007
[TBL] [Abstract][Full Text] [Related]
3. High Performance Anion Exchange and Hydrophilic Interaction Liquid Chromatography Approaches for Comprehensive Mass Spectrometry-Based Characterization of the N-Glycome of a Recombinant Human Erythropoietin.
Szabo Z; Thayer JR; Reusch D; Agroskin Y; Viner R; Rohrer J; Patil SP; Krawitzky M; Huhmer A; Avdalovic N; Khan SH; Liu Y; Pohl C
J Proteome Res; 2018 Apr; 17(4):1559-1574. PubMed ID: 29451981
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Glycosylation Characterization of Recombinant Human Erythropoietin by Electron-Activated Dissociation Mass Spectrometry.
Li X; Wang W; Luo J; Guo L; Zhou Y; Li Y; Chen HX
Appl Biochem Biotechnol; 2024 May; ():. PubMed ID: 38743293
[TBL] [Abstract][Full Text] [Related]
5. Glycan analysis of erythropoiesis-stimulating agents.
Cowper B; Lavén M; Hakkarainen B; Mulugeta E
J Pharm Biomed Anal; 2020 Feb; 180():113031. PubMed ID: 31838284
[TBL] [Abstract][Full Text] [Related]
6. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin.
Skibeli V; Nissen-Lie G; Torjesen P
Blood; 2001 Dec; 98(13):3626-34. PubMed ID: 11739166
[TBL] [Abstract][Full Text] [Related]
7. High-resolution glycoform profiling of intact therapeutic proteins by hydrophilic interaction chromatography-mass spectrometry.
Domínguez-Vega E; Tengattini S; Peintner C; van Angeren J; Temporini C; Haselberg R; Massolini G; Somsen GW
Talanta; 2018 Jul; 184():375-381. PubMed ID: 29674057
[TBL] [Abstract][Full Text] [Related]
8. Doping control analysis of recombinant human erythropoietin, darbepoetin alfa and methoxy polyethylene glycol-epoetin beta in equine plasma by nano-liquid chromatography-tandem mass spectrometry.
Yu NH; Ho EN; Wan TS; Wong AS
Anal Bioanal Chem; 2010 Apr; 396(7):2513-21. PubMed ID: 20148243
[TBL] [Abstract][Full Text] [Related]
9. Glycosylation characterization of recombinant human erythropoietin produced in glycoengineered Pichia pastoris by mass spectrometry.
Gong B; Burnina I; Stadheim TA; Li H
J Mass Spectrom; 2013 Dec; 48(12):1308-17. PubMed ID: 24338886
[TBL] [Abstract][Full Text] [Related]
10. Site-specific qualitative and quantitative analysis of the N- and O-glycoforms in recombinant human erythropoietin.
Jiang J; Tian F; Cai Y; Qian X; Costello CE; Ying W
Anal Bioanal Chem; 2014 Oct; 406(25):6265-74. PubMed ID: 25080026
[TBL] [Abstract][Full Text] [Related]
11. Mass spectrometric glycoform profiling of the innovator and biosimilar erythropoietin and darbepoetin by LC/ESI-MS.
Harazono A; Hashii N; Kuribayashi R; Nakazawa S; Kawasaki N
J Pharm Biomed Anal; 2013 Sep; 83():65-74. PubMed ID: 23708432
[TBL] [Abstract][Full Text] [Related]
12. Glycoform analysis of intact erythropoietin by MALDI FT-ICR mass spectrometry.
Lippold S; Thavarajah R; Reusch D; Wuhrer M; Nicolardi S
Anal Chim Acta; 2021 Nov; 1185():339084. PubMed ID: 34711323
[TBL] [Abstract][Full Text] [Related]
13. Confirmatory analysis of continuous erythropoietin receptor activator and erythropoietin analogues in equine plasma by LC-MS for doping control.
Guan F; Uboh CE; Soma LR; Maylin G; Jiang Z; Chen J
Anal Chem; 2010 Nov; 82(21):9074-81. PubMed ID: 20945883
[TBL] [Abstract][Full Text] [Related]
14. Low LC-MS/MS detection of glycopeptides released from pmol levels of recombinant erythropoietin using nanoflow HPLC-chip electrospray ionization.
Groleau PE; Desharnais P; Coté L; Ayotte C
J Mass Spectrom; 2008 Jul; 43(7):924-35. PubMed ID: 18563860
[TBL] [Abstract][Full Text] [Related]
15. Differentiation and identification of recombinant human erythropoietin and darbepoetin Alfa in equine plasma by LC-MS/MS for doping control.
Guan F; Uboh CE; Soma LR; Birks E; Chen J; You Y; Rudy J; Li X
Anal Chem; 2008 May; 80(10):3811-7. PubMed ID: 18380469
[TBL] [Abstract][Full Text] [Related]
16. Automated High-Throughput Permethylation for Glycosylation Analysis of Biologics Using MALDI-TOF-MS.
Shubhakar A; Kozak RP; Reiding KR; Royle L; Spencer DI; Fernandes DL; Wuhrer M
Anal Chem; 2016 Sep; 88(17):8562-9. PubMed ID: 27479043
[TBL] [Abstract][Full Text] [Related]
17. Differences in sialic acid O-acetylation between human urinary and recombinant erythropoietins: a possible mass spectrometric marker for doping control.
Reichel C
Drug Test Anal; 2013; 5(11-12):877-89. PubMed ID: 24353190
[TBL] [Abstract][Full Text] [Related]
18. Current state and perspectives on erythropoietin production.
Lee JS; Ha TK; Lee SJ; Lee GM
Appl Microbiol Biotechnol; 2012 Sep; 95(6):1405-16. PubMed ID: 22820523
[TBL] [Abstract][Full Text] [Related]
19. An Integrated Strategy Reveals Complex Glycosylation of Erythropoietin Using Mass Spectrometry.
Guan Y; Zhang M; Gaikwad M; Voss H; Fazel R; Ansari S; Shen H; Wang J; Schlüter H
J Proteome Res; 2021 Jul; 20(7):3654-3663. PubMed ID: 34110173
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of erythropoietin biosimilars Epotin™, Hemax® and Jimaixin™ by electrophoretic methods used for doping control analysis and specific N-glycan analysis revealed structural differences from original epoetin alfa drug Eprex®.
Capdeville P; Martin L; Cholet S; Damont A; Audran M; Ericsson M; Fenaille F; Marchand A
J Pharm Biomed Anal; 2021 Feb; 194():113750. PubMed ID: 33234415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
